Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service peripheral nerve stimulation & intrathecal pumps cases in Kansas: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (174 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 10 | 575 | 20% |
| 2020 | 7 | 418 | 23% |
| 2021 | 8 | 406 |
PNS lead and generator, intrathecal pump and catheter. Professional codes (what the surgeon bills): CPT 64555, 64590, 62362, 62350.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 88% of the cases CMS names in Kansas; 8 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Radiofrequency ablation (facet, genicular, basivertebral) | 57 | 3,413+4%/yr | +4%/yr | 8.20.9× | 46% | 4,450 in 2030+4.5%/yr |
| Spinal cord & DRG stimulation |
Peripheral nerve stimulation & intrathecal pumps in every state, and its device makers · Every procedure market in Kansas · Every state · Compare with Ohio
| ≈ 730 |
| – |
| 2026 est. | ≈ 780 | – |
| 28% |
| 2022 | 9 | 461 | 31% |
| 2023 | 14 | 595 | 34% |
| 2024 | 14 | 652 | 36% |
| 2025 from claims | – | 730 591–858 | 36% |
| 2026 forecast | – | 776 608–975 | 36% |
| 2027 forecast | – | 825 612–1,090 | 36% |
| 2028 forecast | – | 876 620–1,209 | 37% |
| 2029 forecast | – | 931 633–1,335 | 37% |
| 2030 forecast | – | 989 648–1,467 | 37% |
In 2025, 2% inpatient hospital, 46% hospital outpatient, 52% surgery center. The share outside the hospital has moved +45 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center |
|---|---|---|---|
| 2026 · ~780 | ~14 | ~340 | ~430 |
| 2027 · ~820 | ~15 | ~350 | ~460 |
| 2028 · ~880 | ~16 | ~360 | ~500 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: surgery center about 57% (52% in 2025), hospital outpatient about 41% (46% in 2025). More of these cases each year are decided in surgery centers, where the surgeons often own the center and weigh price and turnaround.
| 1,1110%/yr |
| 0%/yr |
| 1.5 |
| 70% |
| 1,390 in 2030+3.8%/yr |
| Illinois | 14 | 1,015+11%/yr | +11%/yr | 0.7 | 41% | 2,110 in 2030+13%/yr |
| Missouri | 16 | 810+4.4%/yr | +4.4%/yr | 1.2 | 32% | 1,190 in 2030+6.6%/yr |
| Wisconsin | 8 | 775+8.3%/yr | +8.3%/yr | 1.3 | 50% | 1,500 in 2030+12%/yr |
| Michigan | 9 | 674−6.2%/yr | −6.2%/yr | 0.7 | 49% | 680 in 20300%/yr |
| Minnesota | 10 | 570+1.3%/yr | +1.3%/yr | 1.1 | 65% | 1,150 in 2030+12%/yr |
| Nebraska | 7 | 421+7.4%/yr | +7.4%/yr | 1.5 | 66% | 620 in 2030+6.8%/yr |
| Iowa | 3 | 187+13%/yr | +13%/yr | 0.4 | 34% | 470 in 2030+17%/yr |
| South Dakota | 7 | 186+0.7%/yr | +0.7%/yr | 1.4 | 0% | 230 in 2030+3.3%/yr |
| 19 |
| 505−4.3%/yr |
| −4.3%/yr |
| 1.21.7× |
| 38% |
| 660 in 2030+4.7%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Spr Therapeutics leads with 44% of company spending on these surgeons in 2025, +24 pts on 2024.
In 2025, 8 companies reported engagement with Kansas’s surgeons worth $130K in consulting, speaking, meals and travel tied to these products, about $9,267 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 13 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.